Hayashi J, Kashiwagi S, Noguchi A, Nakashima K, Ikematsu H, Kajiyama W
Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan.
J Infect. 1989 Sep;19(2):119-25. doi: 10.1016/s0163-4453(89)91839-2.
We investigated immune responses in 63 mentally retarded patients each given a low-dose (4 micrograms) intradermally of plasma-derived hepatitis B vaccine made in Japan and which was repeated after 1 and 6 months. Two doses of the vaccine induced antibodies in 85.5% these patients. A further dose 6 months later induced antibodies in 93.5% of the recipients and markedly increased the proportion of recipients with acceptable or high concentrations of antibody. The numbers of acceptable and high responders decreased slightly during a period of 12 months. The rate of acquiring antibody was significantly higher in the males. No significant differences in antibody response with regard to age and type of disease were observed. One patient with Down's syndrome, who acquired a low concentration of antibody after vaccination, was infected with hepatitis B virus. Supplementary vaccination may be necessary for poor responders in order to obtain protection. Side-effects resulting from the vaccination were not severe in any patients. These results suggest that low-dose, intradermal hepatitis B vaccination is safe and effective.
我们对63名智障患者进行了免疫反应研究，这些患者均接受了低剂量（4微克）日本产血浆源性乙肝疫苗的皮内注射，并在1个月和6个月后重复注射。两剂疫苗使85.5%的这些患者产生了抗体。6个月后再注射一剂，使93.5%的接种者产生了抗体，并显著提高了抗体浓度可接受或高浓度的接种者比例。在12个月期间，抗体反应良好和高度反应者的数量略有下降。男性产生抗体的比率明显更高。未观察到在年龄和疾病类型方面抗体反应有显著差异。一名唐氏综合征患者在接种疫苗后产生了低浓度抗体，感染了乙肝病毒。对于反应不佳者，可能需要进行补充接种以获得保护。在任何患者中，接种疫苗产生的副作用都不严重。这些结果表明，低剂量皮内乙肝疫苗接种是安全有效的。
